Acute Myelogenous Lymphoma (AML)

**Relapsed/Refractory disease after 1+ lines**
- CCT5027
  - Phase I FLT3 Chimeric AntigenReceptor T-Cell(CAR-T) AMG 553 in FLT3-Positive Relapsed/Refractory AML
  - PI: Muffy Pending
- BMT330
  - Phase II Very Low Dose Total Body Irradiation in Combination with Total Lymphoid Irradiation and anti-Thymocyte Globulin to Improve Donor Engraftment in Patients Undergoing Non-MHCT
  - PI: Muffy Sponsor: Stanford
- BMT302
  - Phase II Ibrutinib Maintenance After Reduced-Intensity Conditioning &Allogeneic HCT in AcuteLeukemia
  - PI: Rezvani Stanford

**First (CR1)/Second (CR2) Remission**
- BMT322
  - Phase III FLT3Inhibitor Gilteritinib Maintenance Therapy After Allogeneic Transplant in FLT3/ITD AML
  - PI: Muffy BMT CTN

**Advanced Disease**
- FLT3 Mutation
- BMT334
  - Gilteritinib (ASP2215) in FLT3 Mutated Relapsed or Refractory AML or FLT3-Mutated AML in CR w/ MRD
  - PI: Muffy Pending
- BMT336
  - Phase III MAHCT w/ T Cell Depleted Graft w/ Infusion of Conventional and Regulatory T Cells PI: Meyer NIH
  - PI: Meyer NIH

**First (CR1) or Higher Remission**
- Matched Related or Unrelated Donor
- Matched Related Donor
- Haplo

**Key**
- Pending
- Open for Enrollment
- Observational Study
- Link
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu